Medicine News and Research

RSS

LRI and lupus organizations congratulate HGS and GlaxoSmithKline for achieving historical landmark

The Lupus Research Institute (LRI) and its National Coalition of state and local lupus organizations congratulate Human Genome Sciences (HGS) and GlaxoSmithKline for achieving an historical landmark - the second positive phase 3 clinical trial of Benlysta (belimumab), the first successfully tested new drug developed specifically for people with systemic lupus.

2 Nov 2009

BMY and ZGen present Phase 1B results for PEG-Interferon lambda in HCV patients

Bristol-Myers Squibb Company and ZymoGenetics, Inc. today presented final results from a Phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-naïve hepatitis C virus (HCV) patients.

2 Nov 2009

BENLYSTA meets primary endpoint in BLISS-76 trial for systemic lupus erythematosus

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). BLISS-76 study results through 52 weeks showed that belimumab 10 mg/kg plus standard of care achieved a statistically significant improvement in patient response rate as measured by the SLE Responder Index at Week 52, compared with placebo plus standard of care.

2 Nov 2009

Optimer Pharmaceuticals presents additional data from Phase 3 fidaxomicin study

Optimer Pharmaceuticals, Inc. today announced the presentation of new data from fidaxomicin's North American phase 3 study at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia, PA.

2 Nov 2009

ACTwatch data indicates low accessibility of artemisinin combination therapy

ACTwatch, a research project led by PSI, in collaboration with the London School of Hygiene and Tropical Medicine, released evidence today that indicates that artemisinin combination therapy, the most effective medicines for treating malaria, continue to have a significantly low presence on the market among populations considered to be most at risk.

2 Nov 2009

Study examines trajectories in sleep disturbances before and after retirement over an extended time window

A study in the Nov.1 issue of the journal Sleep shows that retirement is followed by a sharp decrease in the prevalence of sleep disturbances. Findings suggest that this general improvement in sleep is likely to result from the removal of work-related demands and stress rather than from actual health benefits of retirement.

2 Nov 2009

CNS cancer survivors have greater neurocognitive dysfunction than survivors of other types of cancer

Brain tumors in childhood cast a long shadow on survivors. The first study of the lasting impact of these tumors -- the most common solid malignancies in childhood -- shows that survivors have ongoing cognitive problems.

2 Nov 2009

Chronically ill patients report better quality of life than those with reversible outcomes

Holding on to hope may not make patients happier as they deal with chronic illness or diseases, according to a new study by University of Michigan Health System researchers.

2 Nov 2009

WCMC-Q's biomedical research program makes significant progress

The biomedical research program of Weill Cornell Medical College in Qatar has made significant progress in its dual goals of advancing basic science and building a sustainable research community in Qatar since it was launched less than a year and a half ago.

2 Nov 2009

Combination of inhibitor and antioxidants may help prevent diabetes complications

In diabetes patients, high blood glucose levels can end up killing certain cells in the eyes and kidneys, which is why diabetes is the leading cause of adult blindness and of kidney failure. Years ago, scientists identified one main route for this destruction—high glucose produces oxidative stress through the NF-kB molecular pathway—but success has been elusive for drugs targeting that pathway.

2 Nov 2009

Employment discrimination based on genetic information prohibited: GINA Title II regulations

The Poster Compliance Center Research Department advises U.S. employers that a revised “Equal Employment Opportunity Is the Law” poster including new information about GINA (Genetic Information Nondiscrimination Act of 2008) was issued by the U.S. Equal Employment Opportunity Commission. The new GINA Title II regulations are effective Nov. 21, 2009.

31 Oct 2009

OMG to conduct Terminology Services Information Day to explore terminology services

OMG(TM) today announced that a special event, Terminology Services Information Day, will be co-located with the OMG Technical Meeting in Long Beach, CA USA on December 8, 2009. For more information and to register for this special event, please visit http://www.omg.org/terminology-services-day.

31 Oct 2009

Amgen publishes Phase 3 study results of Aranesp

Amgen today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes.

31 Oct 2009

London Genetics enters an intensive partnering programme

London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, has entered an intensive partnering programme following on from its successful pharmacogenetic conference in September.

31 Oct 2009

RESPOND program to improve global perspective on emerging diseases

Experts from the University of Minnesota will soon be on the frontlines working to help developing countries better respond to emerging animal diseases that pose a threat to human health.

31 Oct 2009

36-month demonstration program at UCSF reports an 87.7% reduction in medication errors

A 36-month demonstration program at the University of California San Francisco (UCSF) reported this week an 87.7% reduction in medication administration errors – increasing medication administration accuracy to 98% at six Bay Area hospitals.

31 Oct 2009

Molecular imaging pinpoints inflammation in the brains of schizophrenics and migraine sufferers

Inflammatory response of brain cells-as indicated by a molecular imaging technique-could tell researchers more about why certain neurologic disorders, such as migraine headaches and psychosis in schizophrenic patients, occur and provide insight into how to best treat them, according to two studies published in the November issue of the Journal of Nuclear Medicine.

31 Oct 2009

Scientists report a major step forward in the development of an effective therapy against Nipah virus

A collaborative research team from the Uniformed Services University of the Health Sciences (USU), Australian Animal Health Laboratory and National Cancer Institute, a component of the National Institutes of Health, reports a major step forward in the development of an effective therapy against two deadly viruses, Nipah virus and the related Hendra virus.

31 Oct 2009

Patients with disabilities or LEP often perceived that their physicians did not listen to them, find researchers

According to the Institute of Medicine, more than 90 million Americans suffer from low health literacy-, a mismatch between patients' abilities to understand healthcare information and providers' abilities to communicate complex medical information in an understandable manner.

31 Oct 2009

Conference to address the need for gender specific diagnostic strategies for women

The 'Red Alert for Women's Hearts' conference, taking place on 5 November 2009, at the European Heart House, Sophia Antipolis, France, will address the subject of Women and CVD. The conference is jointly organised by the European Society of Cardiology (ESC) and European Heart Network (EHN), as part of Work Package 6 of the EuroHeart project .

31 Oct 2009

Medicine News and Research

LRI and lupus organizations congratulate HGS and GlaxoSmithKline for achieving historical landmark

BMY and ZGen present Phase 1B results for PEG-Interferon lambda in HCV patients

BENLYSTA meets primary endpoint in BLISS-76 trial for systemic lupus erythematosus

Optimer Pharmaceuticals presents additional data from Phase 3 fidaxomicin study

ACTwatch data indicates low accessibility of artemisinin combination therapy

Study examines trajectories in sleep disturbances before and after retirement over an extended time window

CNS cancer survivors have greater neurocognitive dysfunction than survivors of other types of cancer

Chronically ill patients report better quality of life than those with reversible outcomes

WCMC-Q's biomedical research program makes significant progress

Combination of inhibitor and antioxidants may help prevent diabetes complications

Employment discrimination based on genetic information prohibited: GINA Title II regulations

OMG to conduct Terminology Services Information Day to explore terminology services

Amgen publishes Phase 3 study results of Aranesp

London Genetics enters an intensive partnering programme

RESPOND program to improve global perspective on emerging diseases

36-month demonstration program at UCSF reports an 87.7% reduction in medication errors

Molecular imaging pinpoints inflammation in the brains of schizophrenics and migraine sufferers

Scientists report a major step forward in the development of an effective therapy against Nipah virus

Patients with disabilities or LEP often perceived that their physicians did not listen to them, find researchers

Conference to address the need for gender specific diagnostic strategies for women

Everything there is to know about biosimilars eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News